Biologics / Biotechnology

#AI #Assay development optimisation & technology #Biologics / Biotechnology #Cancer research #Drug development #Drug discovery #Vaccines

Latest issue of DDW now available

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as… Read More

#Editor's Choice #News

#Biologics / Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

Seppic boosts presence in the human vaccine adjuvant market

Seppic’s Sepivac SWETM vaccine adjuvant for human use can contribute to the development of vaccine solutions to fight seasonal and pandemic influenza, as well as COVID-19. Together with various international partners, Seppic is participating in the global research effort to develop a vaccine solution against COVID-19. These programs are in… Read More

#Covid-19 #News

#Biologics / Biotechnology #Biomanufacturing #Cell therapy #Drug development

Cedars-Sinai biomanufacturing centre spurs cell therapies to help develop new drugs

Cedars-Sinai has launched a centre to manufacture the next generation of stem cell and gene therapies that will enable biomedical researchers, government medical programs, commercial entities and others to develop new biologic drugs and propel novel disease discoveries. Biologic drugs are produced from living organisms or contain components of living… Read More

#Editor's Choice #News

#Biologics / Biotechnology #CAR-T

Are you interested in reversing the state of T cell exhaustion?

If you are a biotech scientist interested in reversing or overcoming the state of T-cell exhaustion, this webinar will show you how advanced flow cytometry can be used to effectively evaluate immuno-oncology drugs using physiologically relevant assays. Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells for improved… Read More

#News

#Antibodies #Biologics / Biotechnology #Therapeutics

Just-Evotec Biologics gets grant for antibody product for the prevention of COVID-19

Evotec’s Seattle-based subsidiary, Just–Evotec Biologics has received a grant from the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (mAb) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Under… Read More

#Covid-19 #News

#Assays #Biologics / Biotechnology #Drug discovery

Axol Bioscience: multi-electrode array screening for human iPSC-derived cells 

Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, has introduced multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimising hiPSC-derived… Read More

#News

#Antibodies #Biologics / Biotechnology #Biopharma

Bristol Myers Squibb licences IONTAS’ mammalian display technology

IONTAS, a biotechnology company focused on antibody discovery technology development, has entered into a licensing agreement with Bristol Myers Squibb regarding its proprietary mammalian display. Under the terms of this agreement, IONTAS will receive an upfront payment for accessing the technology platform and will work with Bristol Myers Squibb in… Read More

#News

#Biologics / Biotechnology #Concarlo Holdings #Oncology

US biotech start-up set to have huge impact on breast cancer treatment landscape

Backed by more than 20 years of research and development expertise, Concarlo Holdings is developing diagnostics and therapeutics that could have huge impact for metastatic breast cancer patients. Lu Rahman finds out more. Stacy Blain, Co-Founder, Concarlo Holdings, wants to change the conversation around breast cancer. This biotechnology start-up whose… Read More

#Cancer Research #Exclusive Content

#Biologics / Biotechnology #Drug discovery #Japan #NGS #PCR

Big in Japan: SPT Labtech spots biotech growth

SPT Labtech recently opened a new office to maximise on Japanese biotech growth. Lu Rahman caught up with Director Masahiro Matsushita, to find out about the region and the opportunities for drug discovery.   LR: Tell me about the company’s experience in the Japanese biotech market in Japan – how… Read More

#Market Reports

#Analysis #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Immunology #In Silico Biology #Lead discovery #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

Will the next generation of CAR-T cells be modified using base editing?

By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing methodologies such as CRISPR/Cas9, which… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biologics / Biotechnology #High throughput screening #RNA #Screening

Meet Big Tuna: Automated, Versatile Buffer Exchange

Meet Big Tuna: Automated, Versatile Buffer Exchange Sponsored by Unchained Labs Conventional exchange methods are labor-intensive, prone to inconsistency, and difficult to manage in larger numbers. Introduction The critical process of screening formulation buffers to optimize stability is labor intensive and time-consuming, which is often a limiting factor in biologics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Cellular & Molecular biology #Drug development #Immunology #RNA

Meet Stunner: The One-Shot Protein Concentration and Sizing Combo

Meet Stunner: The One-Shot Protein Concentration and Sizing Combo Sponsored by Unchained Labs Stunner pulls double-duty so you don't have to. It's the one and only system that combines high-speed UV/Vis spectral analysis and Dynamic Light Scattering (DLS) for quantifying concentration and nailing down protein stability. Stunner measures highly concentrated… Read More

#Archive

#Biologics / Biotechnology #Clinical trials #Gene therapy #Oncology #RNA

Cobra and the KI collaborate to develop COVID-19 vaccine

The Opencorona consortium has awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak. Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, announced on March 30, they… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology #Immunology / Virology & Vaccines #Pathology #Preclinical #RNA

NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies

The vaccine is currently being evaluated in Phase 3 clinical testing. The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Gene therapy #Microfluidics

Technology developed to rapidly scale up cell and gene therapy manufacture

Image: ThisisEngineering RAEng CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) have collaborated in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies. The technology has the potential to overcome a major bottleneck in the development of these novel… Read More

#News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

Phase III clinical trial of investigational vaccine for COVID-19 begins in US

Multi-site trial to test candidate developed by Moderna and NIH. A Phase III clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna and… Read More

#Covid-19 #News